Pyrazolylaminopyridines as inhibitors of fak
AssigneeGlaxoSmithKline LLC
InventorsJerry Leroy ADAMS, Thomas H. FAITG, Neil W. JOHNSON, Hong LIN, Xin PENG
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R11, R12, R13, Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.
Claims7
The method of inhibiting FAK activity in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of the compound:
- 2-[(5-Chloro-2-{[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino}-4-pyridinyl)amino]-N-(methyloxy)benzamide;
- or a pharmaceutically acceptable salt thereof.
A method of treating or lessening the severity of cancer in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of the compound:
- 2-[(5-Chloro-2-{[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino}-4-pyridinyl)amino]-N-(methyloxy)benzamide;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.